SINGLE-ARM STUDY TO EVALUATE THE SAFETY OF LORLATINIB IN ALK INHIBITOR-TREATED UNRESECTABLE ADVANCED AND/OR RECURRENT ALK-POSITIVE NON-SMALL CELL LUNG CANCER PARTICIPANTS IN INDIA
Latest Information Update: 22 Dec 2024
Price :
$35 *
At a glance
- Drugs Lorlatinib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- Sponsors Pfizer
- 13 Sep 2022 Status changed from active, no longer recruiting to completed.
- 21 Jun 2022 Planned End Date changed from 11 Jul 2022 to 26 Jul 2022.
- 21 Jun 2022 Planned primary completion date changed from 11 Jul 2022 to 26 Jul 2022.